MedPath

Effect of High-dose Pitavastatin on Glucose Control in Patients With Metabolic Syndrome

Registration Number
NCT02940366
Lead Sponsor
Seoul National University Hospital
Brief Summary

This purpose of this study is to evaluate effect of high-dose Pitavastatin on glucose control in patients with metabolic syndrome.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
500
Inclusion Criteria
  • Patients diagnosed as metabolic syndrome according to National cholesterol Education Program criteria
  • Patients with hypercholesterolemia who required to start statin therapy
Exclusion Criteria
  • overt diabetes
  • acute coronary syndrome within 2 months
  • acute cerebrovascular event within 2 months
  • recent treatment of statin within 1month
  • recent diagnosed neoplasm
  • recent diagnosed liver disease
  • chronic kidney disease
  • patients with myopathy
  • pregnant women, nursing mothers, women with possibility of pregnant
  • patients being adminstered cyclosporine
  • patients with genetic disease such as galactose intolerance, lactose intolerance, glucose-galactose malabsorption
  • patients with treatment cyclosporin

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Pitavastatin 4 mg orally dailyPitavastatin 4 mg orally daily-
Atorvastatin 20 mg orally dailyAtorvastatin 20 mg orally daily-
Primary Outcome Measures
NameTimeMethod
Absolute change in HbA1c levelbaselina and after 24months treatment
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath